Eli Lilly and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today announced a strategic collaboration to study real-world evidence and develop new insights to reduce the burden on people living with diabetes.
Companies join forces to advance predictive and prescriptive recommendations for people with diabetes |
| [08-January-2018] |
| INDIANAPOLIS and MOUNTAIN VIEW, Calif., Jan. 8, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Livongo Health, a leading consumer digital health company focused on empowering all people with chronic conditions to live better and healthier lives, today announced a strategic collaboration to study real-world evidence and develop new insights to reduce the burden on people living with diabetes. The research collaboration will combine real-world behavioral studies and claims data to advance knowledge about effective interventions in diabetes care. The companies aim to contribute to medical literature in three areas:
Lilly has been a leader in diabetes care for more than 90 years, and was the first company to make insulin commercially available to people with the disease. Today, Lilly provides a wide range of therapies to address the diverse needs of people living with diabetes. “Collaborating with Livongo is an important step in our research efforts,” said Sherry Martin, MD, vice president of Medical Affairs, Lilly Diabetes. “We hope that our combined expertise will play a key role in empowering people with diabetes to better manage their condition.” Livongo is redesigning chronic condition management, starting with diabetes. Livongo delivers a personalized experience, using data and clinical science, and helps to make staying healthy easier, which results in measurable positive health outcomes for people with diabetes1 and lower costs for payers2. “These studies will have a direct impact on the lives of Livongo members,” said Jennifer Schneider, MD, chief medical officer, Livongo. “Livongo uses reinforcement learning to create customized and actionable insights that guide people to better manage their diabetes. The knowledge we gain from these studies will be incorporated into our diabetes management platform to help drive better health outcomes for our members.” Livongo and Lilly aim to publish the results of their collaborative research studies to further advance diabetes care for people worldwide. About Diabetes About Livongo Health About Lilly Diabetes About Eli Lilly and Company This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about a strategic initiative between Eli Lilly and Company and Livongo Health to study real world evidence and develop new insights to reduce the burden of people living with diabetes, and reflects Lilly’s current belief. However, as with any research collaboration, there are substantial risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of this research collaboration. For further discussion of these and other risks and uncertainties, see Lilly’s most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. P-LLY 01/2018 Lilly USA, LLC 2018. All rights reserved. References
Refer to:
View original content with multimedia:http://www.prnewswire.com/news-releases/livongo-and-lilly-collaborate-on-real-world-diabetes-research-300578410.html SOURCE Eli Lilly and Company; Livongo | ||
Company Codes: NYSE:LLY |
